In utero cannabinoid exposure alters breathing and the response to hypoxia in newborn mice.
Cannabis is one of the most commonly used recreational drugs at ages highly correlated with potential pregnancy. Endocannabinoid signalling regulates important stages of neuronal development. When cannabinoid receptors, which are widely distributed through the nervous system, are activated by exogenous cannabinoids, breathing in adult rats is depressed. Here, we show that, in newborn mice, endocannabinoids, through the activation of cannabinoid receptor type 1 (CB1 R), participate in the modulation of respiration and its control. Blocking CB1 Rs at birth suppressed the brake exerted by endocannabinoids on ventilation in basal and in hypoxic conditions. The number of apnoeas and their duration were also minimized by activation of CB1 Rs in normoxic and in hypoxic conditions. However, prenatal cannabis intoxication, caused by a daily injection of WIN55,212-2, in pregnant mice durably modified respiration of the offspring, as shown by hyperventilation in basal conditions, an altered chemoreflex in response to hypoxia, and longer apnoeas. When CB1 Rs were blocked in WIN55,212-2 treated newborns, persistent hyperventilation was still observed, which could partly be explained by a perturbation of the central respiratory network. In fact, in vitro medullary preparations from WIN55,212-2 treated pups, free of peripheral or of supramedullary structures, showed an altered fictive breathing frequency. In conclusion, the endocannabinoid pathway at birth seems to modulate breathing and protect the newborn against apnoeas. However, when exposed prenatally to an excess of cannabinoid, the breathing neuronal network in development seems to be modified, probably rendering the newborn more vulnerable in the face of an unstable environment.
Institut de Neurosciences de la Timone UMR 7289, Aix Marseille Université, CNRS, Marseille, France.
Keda C
KC
Tree
Maud
M
Scotto di Perretolo
Julie
J
Peyronnet
Florence
F
Cayetanot
D000818:Animals; D000831:Animals, Newborn; D001049:Apnea / Q000188:drug therapy / Q000503:physiopathology; D048588:Benzoxazines / Q000009:adverse effects*; D063386:Cannabinoid Receptor Agonists / Q000009:adverse effects*; D063387:Cannabinoid Receptor Antagonists / Q000494:pharmacology; D005260:Female; D000860:Hypoxia / Q000188:drug therapy / Q000503:physiopathology*; D007150:Immunohistochemistry; D008526:Medulla Oblongata / Q000187:drug effects / Q000254:growth & development / Q000503:physiopathology; D008810:Mice, Inbred C57BL; D009025:Morpholines / Q000009:adverse effects*; D009281:Naphthalenes / Q000009:adverse effects*; D010507:Periodicity; D010880:Piperidines / Q000494:pharmacology; D010991:Plethysmography; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011720:Pyrazoles / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism; D012119:Respiration / Q000187:drug effects; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D048588:Benzoxazines; D063386:Cannabinoid Receptor Agonists; D063387:Cannabinoid Receptor Antagonists; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; C103505:AM 251; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D014446:Tyrosine 3-Monooxygenase
CB1R; cannabis; lack of oxygen; neonate; prenatal